HOME EDITORIAL BOARD CONTACT US SUBSCRIPTION AUTHORS INDEX AUTHORS INSTRUCTIONS SUPPLEMENTARY DATA




   
 VOLUME 13 - NUMBER 2
/ April - June 2011

 
European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update
Anne-Mieke Vandamme, Ricardo J. Camacho, Francesca Ceccherini-Silberstein, Andrea de Luca, Lucia Palmisano, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Jean-Claude Schmit, Vincent Soriano, Hauke Walter, Anders Sönnerborg and the European HIV Drug Resistance Guidelines Panel |Full Article in PDF|
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
 
Abstract

The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.

 
Key words:
HIV. Antiviral therapy. Drug resistance testing. Guidelines. Genotype. Phenotype.
 
Date: 30/08/2014
ISSN: 1698-6997

 

unsubscribe 

LOGIN 
Not a member?
REGISTER 

Editor's access. 

PERMANYER PUBLICATIONS
Mallorca, 310
08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
www.permanyer.com
LINKS:
Hepatology Reviews
Hepatology Reviews
 
Cancer & Chemotherapy Reviews
Cancer & Chemotherapy
Reviews
 
trends in transplantation
Trends in Transplantation


 
© 2014 Permanyer Publications
Made & Powered by IMMA PUIG
Mallorca, 310 - 08037 Barcelona, Spain. Tel.: +34 93 207 59 20 - Fax: +34 93 457 66 42